Stevanato Group S.p.A. filings document the company’s reporting as a foreign private issuer and its business in drug containment, drug delivery and diagnostic solutions. Form 6-K reports furnish interim financial statements, results press releases, investor presentations and conference call materials covering revenue trends, segment performance, high-value solutions, margins, guidance, capacity expansion and risk disclosures.
Governance filings also include shareholder meeting notices, explanatory reports, sustainability reporting, committee reports, remuneration policy materials, dividend allocation matters and director slate information. These documents describe the company’s financial reporting framework, board and committee processes, shareholder voting matters and public-company disclosures for STVN.
Stevanato Group S.p.A. Chief Business Strategy Officer Mauro Stocchi reported a direct sale of 13,649 ordinary shares on September 28, 2026, at $21.50 per share. His reported direct holdings after the sale were 400,000 shares. No Rule 10b5-1 plan is reported. A footnote says his Form 3 filed March 18, 2026, inadvertently omitted 20 ordinary shares and that this filing correctly reflects his holdings.
Stevanato Group S.p.A. (STVN) has a notice under Rule 144 indicating that officer Mauro Stocchi may sell 13,649 ordinary shares, with an aggregate market value of $276,255, through Banca Generali on or after September 14, 2026 on the NYSE. The notice states that 302,842,536 shares were outstanding and that the securities to be sold were acquired as a stock award on September 6, 2025, for cash consideration.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of common stock of Stevanato Group S.p.A. as of June 30, 2026. The firm reports beneficial ownership of 3,921 shares, representing 0.0% of the class. It has sole voting power and sole dispositive power over all 3,921 shares, with no shared voting or dispositive power. The filer states that this reflects ownership of 5 percent or less of the class and expressly denies that the filing should be construed as an admission of beneficial ownership of the securities referred to.
Artisan Partners entities report a significant holding in Stevanato Group S.p.A. They report beneficial ownership of 2,601,598 ordinary shares, representing 5.2% of the class, based on 49,709,718 shares outstanding as of 03/31/2026.
The group has shared voting power over 1,809,760 shares and shared dispositive power over 2,601,598 shares, with no sole voting or dispositive power. The shares are held on behalf of discretionary clients of Artisan Partners Limited Partnership, and those clients receive dividends and sale proceeds. To the filers’ knowledge, no individual client has an economic interest in more than 5% of the class.
Stevanato Group S.p.A. director Luciano Santel reported a sale of 2,023 Ordinary Shares on 2026-08-07. The shares were sold primarily to cover tax obligations associated with a grant of ordinary shares, at a weighted average price of $20.09 per share, across multiple trades between $19.95 and $20.22. Following this transaction, Santel directly holds 4,739 Ordinary Shares of Stevanato Group S.p.A.
Stevanato Group S.p.A. Chief Financial Officer Marco Dal Lago reported a sale of 4,209 Ordinary Shares of Stevanato Group on 2026-08-07. The shares were sold primarily to cover tax obligations associated with a grant of ordinary shares, at a weighted average price of $20.09 per share, in multiple trades between $19.95 and $20.22. Following this tax-related sale, Dal Lago directly holds 81,144 Ordinary Shares of Stevanato Group.
Stevanato Group S.p.A. director Elisabetta Magistretti reported selling 2,045 Ordinary Shares of STVN on 2026-08-07 at a weighted average price of $20.09 per share, in multiple trades between $19.95 and $20.22. The sale was made to cover tax obligations related to a grant of ordinary shares. Following this transaction, she directly holds 2,930 Ordinary Shares.
Stevanato Group S.p.A. reported Q2 2026 revenue of €302 million, up 8% year over year, with 9% growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment offsetting a 2% decline in Engineering. Adjusted EBITDA margin was 26%, supported by a 16% increase in High Value Solutions revenue, which reached 45% of total sales; GLP‑1–related products contributed about 22%–23% of company revenue.
Management updated 2026 guidance to revenue of €1.260 billion–€1.280 billion, adjusted EBITDA of €335 million–€345.2 million (implying a 26.8% margin at the midpoint), and adjusted diluted EPS of €0.60–€0.62. Free cash flow is expected between breakeven and €20 million, with High Value Solutions targeted at 47%–48% of revenue and BDS growing high‑single‑digits while Engineering declines mid‑single‑ to low‑double‑digits.
The company completed the divestiture of its California-based Balda C. Brewer subsidiary, which had about €30 million of annual revenue and slightly positive EBITDA, describing the move as margin accretive and aligned with its focus on biologics, GLP‑1 therapies and proprietary drug‑delivery platforms such as Alina®, Deora™ and Alba® syringes. Guidance attributes overall margin expansion to a richer mix of High Value Solutions and improving efficiency as new facilities in Fishers and Latina ramp toward full utilization through 2028.
Stevanato Group S.p.A. reported interim results for the three and six months ended June 30, 2026. Revenue was about €302.0M for the quarter and €575.6M for the half year, up from €280.0M and €536.6M. Gross profit rose to €162.0M for the half, while operating profit was €77.8M.
Net profit was €23.0M for the quarter and €51.0M for the half year, compared with €29.7M and €56.2M, reflecting a €12.2M loss on the sale of Balda C. Brewer Inc. and a higher effective tax rate of 34.1%. High-value solutions revenue increased to €264.5M from €227.1M. Cash flow from operating activities was €107.4M, while capital expenditure, including €123.9M for property, plant and equipment, supported ongoing global capacity expansion. Total assets were €2.62B and equity €1.55B at June 30, 2026.